Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 29, 2010, Pages 13069-13074

  Sarosiek, Kristopher A ^a,b   Cavallin, Lucas E ^a   Bhatt, Shruti ^a,b   Toomey, Ngoc L ^b   Natkunam, Yasodha ^a   Blasini, Wilfredo ^c   Gentles, Andrew J ^c   Ramos, Juan Carlos ^a,b   Mesri, Enrique A ^a,b   Lossos, Izidore S ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Herpesvirus 8; Kaposi's sarcoma associated herpesvirus

Indexed keywords

BORTEZOMIB; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTOME;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER REGRESSION; CASE REPORT; CELL CULTURE; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG EFFICACY; GENE CONTROL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; OVERALL SURVIVAL; PERITONEAL CAVITY; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CERCOPITHECUS AETHIOPS; DNA REPLICATION; DOWN-REGULATION; E2F3 TRANSCRIPTION FACTOR; FATAL OUTCOME; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; MALE; MICE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNFOLDED PROTEIN RESPONSE; VERO CELLS; VIRION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; HUMAN HERPESVIRUS 8; MUS;

EID: 77955590822     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002985107     Document Type: Article

References (49)

1. Chang Y, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
2. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191.
3. Cesarman E, Knowles DM (1999) The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Semin Cancer Biol 9:165-174. (Pubitemid 29273833)
4. Carbone A, et al. (2005) Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: A tissue-based variant of primary effusion lymphoma. J Mol Diagn 7:17-27. (Pubitemid 40310161)
5. Simonelli C, et al. (2003) Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol 21:3948-3954. (Pubitemid 46606208)
6. Jones D, et al. (1998) Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 339:444-449. (Pubitemid 28377686)
7. Chen YB, Rahemtullah A, Hochberg E (2007) Primary effusion lymphoma. Oncologist 12:569-576.
8. Judde J-G, et al. (2000) Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 92:729-736.
9. Ballestas ME, Kaye KM (2001) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol 75:3250-3258.
10. Renne R, et al. (1996) Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2:342-346. (Pubitemid 26080656)
11. Sun R, et al. (1999) Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73:2232-2242. (Pubitemid 29098128)
12. Guasparri I, Keller SA, Cesarman E (2004) KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199:993-1003. (Pubitemid 38481090)
13. Boulanger E, et al. (2005) Prognostic factors and outcome of human herpesvirus 8- associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23: 4372-4380. (Pubitemid 46207011)
14. Toomey NL, et al. (2001) Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 20:7029-7040.
15. Wu W, Rochford R, Toomey L, Harrington W, Jr, Feuer G (2005) Inhibition of HHV-8/ KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res 29:545-555.
16. Keller SA, Schattner EJ, Cesarman E (2000) Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96:2537-2542.
17. An J, Sun Y, Fisher M, Rettig MB (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18:1699-1704.
18. Klass CM, Krug LT, Pozharskaya VP, Offermann MK (2005) The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 105:4028-4034.
19. Staudt MR, et al. (2004) The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 64:4790-4799.
20. Parravicini C, et al. (2000) Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156:743-749.
21. Obeng EA, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107:4907-4916.
22. Nikrad M, et al. (2005) The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 4: 443-449.
23. Richardson PG, et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498.
24. O'Connor OA, et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684.
25. Guasparri I, Wu H, Cesarman E (2006) The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep 7:114-119.
26. Jenner RG, et al. (2003) Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA 100:10399-10404.
27. Drexler HG, Uphoff CC, Gaidano G, Carbone A (1998) Lymphoma cell lines: In vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia 12:1507-1517.
28. Lee AS (2005) The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 35 (4):373-381.
29. Rowlands AG, Panniers R, Henshaw EC (1988) The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. J Biol Chem 263:5526-5533.
30. Harding HP, et al. (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6:1099-1108.
31. Zeller KI, et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 103:17834-17839.
32. Bild AH, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
33. Hamamura RS, et al. (2007) Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer 97:1099-1105.
34. Hideshima T, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
35. Cannon ML, Cesarman E (2004) The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene 23:514-523.
36. Montaner S, Sodhi A, Pece S, Mesri EA, Gutkind JS (2001) The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 61:2641-2648.
37. Bhatt AP, et al. (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463.
38. Chen KF, et al. (2009) Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284: 11121-11133.
39. Bubman D, Guasparri I, Cesarman E (2007) Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26:4979-4986.
40. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199-207.
41. Wu M, et al. (1996) Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol 16:5015-5025. (Pubitemid 26272156)
42. Nilsson JA, Cleveland JL (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22:9007-9021.
43. Sarosiek KA, et al. (2010) Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 115:570-580.
44. Brown HJ, McBride WH, Zack JA, Sun R (2005) Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther 10:745-751.
45. Arvanitakis L, et al. (1996) Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88:2648-2654.
46. Kurokawa M, et al. (2005) Azidothymidine inhibits NF-kappaB and induces Epstein- Barr virus gene expression in Burkitt lymphoma. Blood 106:235-240.
47. Mutlu AD, et al. (2007) In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: A cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 11:245-258.
48. Lossos IS, et al. (2000) Molecular analysis of immunoglobulin genes in diffuse large Bcell lymphomas. Blood 95:1797-1803.
49. Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS (2009) Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. Br J Haematol 147: 308-318.